|Day Low/High||43.52 / 45.93|
|52 Wk Low/High||34.53 / 96.59|
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.
Confirming Guidance for Phase 3 Data Readout for SPK-RPE65 in 2015; Pipeline Advancing and Expanding
Spark Therapeutics (ONCE) stock is rising after Jim Cramer spoke with co-founder and CEO Jeff Marrazzo on CNBC's Mad Money show Wednesday night.
Cramer says Fitbit, Ambarella and GoPro may not be too expensive to own with their growth rates and market potential.
Cramer is not worried about Apple, and suggests viewers sit back and wait until the post-earnings panic subsides.
Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.
Cramer said Chevron's too cheap, he likes Sun Edison over Canadian Solar and wants you to buy Box.
Today the Federal Reserve told us what we already knew about the U.S. economy, Cramer says.
Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.
After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.
Shares of Spark Therapeutics, a company investigating gene therapy whose most advanced product candidate, is being studied as a treatment of rare blinding conditions, is falling in early trading...
Will the failure of Celladon's Mydicar gene therapy bring other high-flying gene therapy stocks down to Earth?
Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?
These are the top five best IPO performers in the last 12 months.
Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
Cramer wants you to avoid Pacific Ethanol, Sanchez Energy and Micron but buy, buy, buy Alcoa.
It's creating investment opportunities that just shouldn't exist, Cramer says.
Investors were eating up shares of Shake Shack as the stock more than doubled after the fast-casual burger chain's stock debuted on the New York Stock Exchange.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.